UK Prime Minister to meet with brain cancer patient after research appeal
The UK's Prime Minister, Andy Burnham, has agreed to meet with a Team GB swimmer who suffers from brain cancer…
Oncology
-
-
ASCO26: AI innovations show promise in reducing the oncology RWD burden
Artificial intelligence (AI) was a hot topic on the agenda at the American Society of Clinical Oncology (ASCO) meeting 2026,…
-
China’s rapid rise in drug development casts a long shadow over US oncology
2026 marks a clear turning point for China’s position in the global clinical trials arena, particularly in oncology. At this…
-
Summit debuts longer-term ivonescimab data as it awaits FDA NSCLC decision
Summit Therapeutics has released more Phase III trial data for ivonescimab in non-small cell lung cancer (NSCLC) as it awaits…
-
Nuvation Bio to advance glioma drug to Phase III trial after positive three-year data
Nuvation Bio’s glioma drug has touted a 36-month progression-free survival (PFS) rate of 79% with nearly 40 months of follow-up, with its advancement to…
-
Agenus’ metastatic colorectal cancer combo achieves 33% three-year OS rate
Agenus’s metastatic colorectal cancer (mCRC) combination therapy has continued to show benefit after three years of treatment, with a median…
-
Genmab and AbbVie’s Epkinly combo improves PFS in second-line DLBCL trial
Genmab’s Phase III trial of a combination therapy including its bispecific T-cell engager (BiTE) combination, including Epkinly, has met its…
-
Novocure’s Optune Gio fails to show benefit at earlier stage
Novocure’s stock has dropped more than 15% after its Phase III glioblastoma study of Optune Gio failed to show benefit…
-
Verastem Oncology’s pancreatic cancer combo shows 86% OS rate
Verastem Oncology’s pancreatic cancer combination has shown an 86% overall survival (OS) rate in a Phase Ib/IIa trial. In the…
-
EHA26: BTK combos in CLL/SLL showing earlier line promise
At the European Hematology Association (EHA) 2026 Congress, several therapies for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma…
